文献速递心律失常心力衰竭与心肌病

肥厚型心肌病合并心房颤动的当代管理进展

Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
PubMed 文献 · Circulation · 2023-11-27

心房颤动是肥厚型心肌病(HCM)最常见的持续性心律失常,临床和亚临床发作接近半数患者。HCM合并房颤历史上与血栓栓塞性卒中及发病率和死亡率增加相关,但治疗策略的进步改善了预后。系统口服抗凝药(首选直接口服抗凝药)显著降低卒中风险,HCM专用HCM-AF评分可识别未来房颤风险,节律控制对症状明显者必要,导管消融和外科迷宫术为部分患者提供选择。

要点

  • HCM合并房颤患者应在首次临床房颤发作后启动口服抗凝,优先选择直接口服抗凝药而非华法林。
  • CHA2DS2-VASc评分不适用于HCM患者的抗凝决策,HCM-AF评分可识别未来房颤风险。
  • 症状明显的房颤患者需恢复并维持窦性心律,导管消融单次成功率较低但多次消融联合抗心律失常药可提高窦律维持率。

核心结论

  • 当代治疗策略使绝大多数HCM合并房颤患者生活质量改善且HCM相关死亡率低。

主要发现

  • 房颤在HCM中临床和亚临床发作接近半数患者。
  • 系统口服抗凝(首选直接口服抗凝药)显著降低HCM患者卒中风险。
  • 单次导管消融后3年无房颤率约35%,多次消融联合抗心律失常药可使超过三分之二患者5年维持窦律。
  • 肌切除术中辅以双心房Cox-Maze IV外科消融可使70%患者5年无房颤发作。

关键数值与推荐

  • CHA2DS2-VASc评分在HCM中信息价值有限,低评分患者仍可能发生卒中,不应据此决定抗凝。
  • HCM-AF评分可可靠识别大多数未来有房颤风险的HCM患者。
  • 索他洛尔、丙吡胺和胺碘酮可有效抑制房颤发作,但长期疗效数据有限。

临床怎么用

  • 首次临床房颤发作后启动口服抗凝,优先选用直接口服抗凝药。
  • 使用HCM-AF评分评估未来房颤风险,不依赖CHA2DS2-VASc评分决定抗凝。
  • 无症状或轻微症状患者可控制心室率,症状明显且生活质量受损者需节律控制。
  • 导管消融可作为部分患者的治疗选择,必要时多次消融联合抗心律失常药。
  • 肌切除术中可考虑辅以双心房Cox-Maze IV外科消融。

局限性

  • 抗心律失常药长期疗效仅由有限数据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of patients. AF in HCM historically has been characterized as a decisive disease complication associated with substantial risk for thromboembolic stroke and increased morbidity and mortality. However, there have been many advances in treatment strategy resulting in improved outcomes for this patient group. For example, stroke risk in HCM has been greatly reduced by using systemic oral anticoagulation initiated after the first clinical (symptomatic) AF episode, usually with preference given to direct anticoagulants over warfarin. In contrast, stroke risk scoring systems (such as CHA2DS2-VASc score) are not informative in HCM given the substantial potential for stroke events in patients with low scores, and therefore should not be used for anticoagulation decisions in this disease. A novel risk score specifically designed for HCM (HCM-AF score) can reliably identify most patients with HCM at risk for future AF. Although a strategy focused on controlling ventricular rate is effective in asymptomatic (or minimally symptomatic) patients with AF, restoring and maintaining sinus rhythm is required for most patients with marked AF symptom burden and impaired quality of life. Several antiarrhythmic drugs such as sotalol, disopyramide, and amiodarone, can be effective in suppressing AF episodes; albeit safe, long-term efficacy is supported by only limited data. Catheter AF ablation has emerged as an important treatment option for some patients, although freedom from AF after a single ablation is relatively low (35% at 3 years), multiple ablations and the concomitant use of antiarrhythmic drugs can control AF with more than two-thirds of patients maintaining sinus rhythm at 5 years. Surgical AF ablation with biatrial Cox-Maze IV performed as an adjunctive procedure during myectomy can reduce symptomatic AF episodes (70% of patients free from AF at 5 years). For the vast majority of patients who have HCM with AF, the implementation of contemporary therapies has allowed for improved quality of life and low HCM-related mortality.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rowin, Link, Maron, et al. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2023. PMID: 38011245. doi:10.1161/CIRCULATIONAHA.123.065037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。